Catalyst Pharmaceuticals' investment merits are bolstered by a favorable settlement announced on 01/08/2025. CPRX generates income from three products, primarily FIRDAPSE for LEMS and FYCOMPA for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results